Directorate Change

Cambridge Cognition Holdings PLC

18 October 2024

 

18 October 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Directorate change

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that, further to the announcement made on 12 September 2024 in which it stated that Dr Matthew Stork had stepped down as Chief Executive Officer, the Company has now received the formal resignation of Dr Stork as a Director of the Company and all subsidiary entities of which he was a Director. 

Enquiries:

Cambridge Cognition Holdings plc  Dr Steven Powell, Chairman c/o Hudson Sandler  Panmure Liberum Limited (NOMAD and Joint Broker)  Freddy Crossley / Will Goode / Mark Rogers  Rupert Dearden  Tel: [phone]  (Corporate Finance)  (Corporate Broking)  Dowgate Capital Limited (Joint Broker)  David Poutney / James Serjeant  Tel: [phone]  Hudson Sandler (Financial PR and IR)  Dan de Belder / Hattie Dreyfus / Harry Griffiths Tel: [phone]  [e-mail]

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit: https://cambridgecognition.com/

 

END